^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    3ms
    A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=187, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Hetronifly (serplulimab) • tambotatug pelitecan (RG6919)
    3ms
    Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. (PubMed, J Clin Invest)
    Lastly, enhanced in vivo antitumor activity of vobramitamab duocarmazine by systemic A-1331852 was shown. Collectively, our findings provide rationale for the development of ADC therapies combining genotoxic payloads with BCL-XL inhibitors for mCRPC.
    Journal
    |
    CD276 (CD276 Molecule) • BCL2L1 (BCL2-like 1) • STEAP1 (STEAP Family Member 1)
    |
    A-1331852 • vobramitamab duocarmazine (MGC018)
    3ms
    MGC018-SCLC: MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, Georgetown University | Trial completion date: May 2026 --> Apr 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    vobramitamab duocarmazine (MGC018)
    3ms
    A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=36, Completed, Innovent Biologics (Suzhou) Co. Ltd. | N=180 --> 36
    Enrollment change • First-in-human
    3ms
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=594, Recruiting, BioNTech SE | Trial completion date: Jun 2031 --> May 2032 | Trial primary completion date: Aug 2027 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    pumitamig (BNT327) • BNT324
    3ms
    DB-1311-201: DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (2025-523895-22-00)
    P1/2, N=102, Not yet recruiting, Dualitybio Inc. | N=57 --> 102
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    3ms
    Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges. (PubMed, Front Immunol)
    Several next-generation ADC programmes, including PSMA- and B7-H3-directed agents such as MEDI3726 and DS-7300, have reported early antitumour activity signals. At the same time, the global development landscape remains fragmented across targets, payload classes, endpoints, and sponsor types. This study therefore aimed to map the contemporary landscape of ADC clinical trials for prostatic neoplasms, clarify current development patterns, identify translational opportunities and gaps, and provide an integrated overview to support future clinical development.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    ifinatamab deruxtecan (DS-7300) • MEDI3726
    4ms
    QLC5508 in Participants With Metastatic Prostate Cancer (clinicaltrials.gov)
    P3, N=700, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    docetaxel • MHB088C
    4ms
    BGB-C354-101: A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Completed, BeOne Medicines | Active, not recruiting --> Completed | N=120 --> 63 | Trial completion date: Jan 2027 --> May 2026 | Trial primary completion date: Dec 2026 --> May 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Tevimbra (tislelizumab-jsgr)
    4ms
    A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) (clinicaltrials.gov)
    P1/2, N=134, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    ifinatamab deruxtecan (DS-7300)
    4ms
    A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (clinicaltrials.gov)
    P3, N=494, Not yet recruiting, Hansoh BioMedical R&D Company
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • risvutatug rezetecan (GSK5764227)
    4ms
    QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    |
    Nubeqa (darolutamide) • itraconazole • MHB088C • rifampicin